← Organon & Co. (OGN) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Organon & Co. (OGN)
Pharmaceutical Preparations · market cap $3.6B · as of 2026-07-14
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-09 (est.)
Earnings
Pipeline
20
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Organon & Co. (OGN) is a specialty pharmaceutical company spun out of Merck, focused on women's health (reproductive medicine, contraception, HRT), biosimilars, and established brands across psychiatry and anesthesia. With ~$6.2B in annual revenue but $7.47B in net debt against a $3.55B market cap, the equity is a highly leveraged claim on a largely mature, off-patent portfolio. The August 4, 2026 earnings print is the nearest near-term catalyst.
The catalyst path
- 2026-11-09 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| MK0217, alendronate sodium / Duration of Treatment : 2 Years | Phase 3 | Osteoporosis, Postmenopausal |
| Corifollitropin alfa | Phase 3 | In Vitro Fertilization |
| Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 25 mcg | Phase 2 | Asthma |
| Tibolone 2.5 mg | Phase 3 | Postmenopausal Women |
| Desloratadine 2.5 mg | Phase 2 | Post-nasal Drip |
| MK0663, Etoricoxib / Duration of Treatment : 12 Weeks | Phase 3 | Recurrent Low Back Pain |
| A-Phase: tirofiban; Z-Phase simvastatin | Phase 3 | Acute Coronary Syndrome |
| Radiopaque Implanon | Phase 3 | Contraception |
| NOMAC-E2 | Phase 3 | Contraception |
| Desloratadine (Clarinex) | Phase 3 | Allergic Rhinitis |
| tibolone | Phase 3 | Sexual Dysfunction |
| Desloratadine 5 mg | Phase 3 | Eczema |
| tapinarof cream, 1% | Phase 3 | Plaque Psoriasis |
| etoricoxib | Phase 2 | Rheumatoid Arthritis |
| phenylephrine | Phase 3 | Rhinitis, Allergic, Seasonal |
| 5-mg Desloratadine | Phase 3 | Rhinitis, Allergic, Seasonal |
| asenapine | Phase 3 | Schizophrenia |
| Mometasone Furoate Nasal Spray (MFNS) | Phase 3 | Nasal Polyps |
| Mometasone Furoate/Formoterol Fumarate (MF/F) 100/5 mcg MDI | Phase 3 | Asthma |
| DRSP-EE | Phase 3 | Contraception |
Price & technical context
3-month
+1.2%
6-month
+123.3%
12-month
+28.4%
52-wk range
$5.70–$13.78
vs 50-day MA
+0.3%
vs 200-day MA
+26.3%
Realized vol
62.7%
Max drawdown
-73.3%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for OGN (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.